Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,479.00+4.36%ETH$2,418.76+6.50%GOLD$4,105.50+0.80%OIL$87.81-0.35%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANGO

AngioDynamics, Inc.

Healthcare · Medical - Instruments & Supplies

$11.73

Up+$0.52 (+4.43%)

Updated Nov 5, 2026, 1:00 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
471.53M
P/E ratio
-17.09
Dividend yield
0.00%
52-week range
$9.39 – $16.29
Volume
1.22M
Avg. volume
570.39K

Price performance · ANGO

ANGO price history

1M range · 0 trading sessions · Daily adjusted prices

ANGO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ANGO news

The latest Smart Investors Daily articles mentioning ANGO.

Stock researchCompany · Overview

ANGO research

Overview

Company profile and research snapshot.

Company profile

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
ANGO recent ratings
DateFirmRatingTarget
Oct 13, 2026HC Wainwright & Co.Buy—
Oct 9, 2026Canaccord GenuityBuy—
Jul 15, 2026HC Wainwright & Co.Buy—
Jul 15, 2026Canaccord GenuityBuy—
Apr 6, 2026Freedom BrokerBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

LATHAM, N.Y., October 21, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in

Yahoo · Oct 14, 2026

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

LATHAM, N.Y., October 14, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By